MNOV

Business Context and Reporting Period

Company: MediciNova, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 14, 2005
Reporting Period: Quarter ended September 30, 2005 (supplementing Form 10-Q)
Context: The filing provides supplemental information regarding a Japanese report ("Kessan Tanshin") filed with the Osaka Securities Exchange. It clarifies accounting differences between Japanese reporting standards and U.S. GAAP, specifically regarding equity per share calculations, liability classifications for preferred stock, and asset changes following the company's Initial Public Offering (IPO).

Key Financial Metrics

Stockholders' Equity:

• September 30, 2005: $142,936,535
• December 31, 2004: $7,669,122

Stockholders' Equity Per Share:

• September 30, 2005: $1.45 (based on 98,855,856 shares outstanding)
• December 31, 2004: $15.34 (based on 500,000 shares outstanding)

Total Liabilities:

• September 30, 2005: $5.0 million
• December 31, 2004: $46.1 million (Japanese report basis including redeemable preferred stock as liability)
• December 31, 2004: $2.6 million (U.S. GAAP basis per Form 10-Q)

Assets:

• Prepaid expenses and other current assets: Increased from $0.5 million (Dec 31, 2004) to $1.9 million (Sep 30, 2005).
• Other assets: Decreased from $2.2 million (Dec 31, 2004) to $0 (Sep 30, 2005).

Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, net income, or operating cash flow for the period.

Material Changes Versus Prior Period

Equity and Share Count: Significant increase in total stockholders' equity and outstanding shares due to the completion of the IPO during the period. The share count increased from 500,000 to 98,855,856.

Liabilities: Total liabilities decreased by approximately $41.1 million (from $46.1 million to $5.0 million) in the Japanese report. This reduction is attributed to the elimination of the redemption right for Series C Preferred stock upon its automatic conversion to common stock during the IPO.

Asset Composition:

• Prepaid Expenses: Increased by $1.4 million, driven by $0.9 million in prepaid expenses to contract research organizations (CROs), $0.3 million in insurance premiums, and $0.2 million in interest receivable.
• Other Assets: Decreased by $2.2 million as IPO-related costs were deducted directly from stockholders' equity rather than remaining as assets.

Guidance, Outlook, and Risks

Outlook: The company confirmed it has not changed its estimated results of operations for the full year 2005 from those previously disclosed in the Kessan Tanshin filed on August 16, 2005.

Accounting Differences: The filing highlights a material difference in the classification of redeemable convertible preferred stock. The Japanese report classifies this as a liability, whereas U.S. GAAP (used in the 10-Q) does not, resulting in a significant variance in reported total liabilities for the prior year-end.

Risks and Forward-Looking Statements: The report contains forward-looking statements subject to risks and uncertainties that may cause actual results to differ materially. Investors are directed to the Form 10-Q and Prospectus Supplement for a detailed discussion of these factors.

Investor Verification Checklist

• Verify the reconciliation of the $46.1 million vs. $2.6 million liability figures for December 31, 2004, to understand the impact of preferred stock classification on leverage ratios.
• Confirm the exact number of shares outstanding (98,855,856) and the corresponding equity per share ($1.45) as of September 30, 2005.
• Review the Form 10-Q for the quarter ended September 30, 2005, to obtain specific revenue and net income figures not included in this 8-K.
• Examine the August 16, 2005 Kessan Tanshin to compare the full-year 2005 operational estimates against actual performance.
• Assess the impact of the $1.4 million increase in prepaid CRO expenses on future operating cash flow requirements.